证券代码：603014 证券简称：威高血净 公告编号：2025-044 山东威高血液净化制品股份有限公司 第二届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 山东威高血液净化制品股份有限公司（以下简称"威高血净"或"公司"）第二届董 事会第十八次会议于 2025 年 11 月 20 日以现场和通讯相结合的方式在公司会议室召 开，会议通知于 2025 年 11 月 16 日通过通讯方式送达全体董事。本次会议由董事长 宋修山召集并主持，会议应出席董事 9 人，实际出席董事 9 人；公司部分高级管理 人员列席了本次会议。本次会议的召集、召开和表决程序符合《中华人民共和国公 司法》等法律、法规、部门规章、规范性文件和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事审议，并对议案进行了投票表决，通过了以下决议： （一）审议通过了《关于对合营企业同比例增资暨关联交易的议案》 具体内容详见公司同日刊登于上海证券交易所网站（www.sse.com.cn）及公司指 定信息披露媒体 ...

Core Viewpoint - Weigao Blood Purification (603014.SH) announced a capital increase to support the development of its peritoneal dialysis fluid business through a joint investment with Taimao (China) Investment Co., Ltd. [1] Group 1 - The company plans to increase its capital by 72.5 million RMB [1]

Group 1 - The 18th China-EU Investment Trade and Technology Cooperation Fair will be held in Chengdu from November 19 to 21, focusing on bilateral economic and trade relations, industrial chain, and supply chain cooperation [1] Group 2 - A total of 7 companies will have their restricted shares unlocked today, with a total unlock volume of 5.5992 million shares, amounting to a market value of 225 million yuan [3] - The companies with the highest unlock volumes are Haishike, Taili Technology, and Weigao Blood Products, with unlock shares of 1.74 million, 1.2639 million, and 1.2547 million respectively [3] - In terms of market value, Haishike, Weigao Blood Products, and Taili Technology lead with unlock values of 95.1606 million yuan, 51.6328 million yuan, and 48.7358 million yuan respectively [3] Group 3 - 15 companies have disclosed their stock repurchase progress, with 2 companies announcing new repurchase plans, 2 companies having their plans approved by shareholders, and 8 companies completing their repurchase plans [4] - Midea Group and Hualu Hengsheng have announced new repurchase plans of up to 5.3696 million yuan and 542,400 yuan respectively [4] - Meizhi Gao and Yaoji Technology have plans approved for repurchase of up to 24.763 million yuan and 290,500 yuan respectively [4]

从解禁股数占总股本比例来看，太力科技、方盛股份、威高血净解禁比例居前，解禁比例分别为 1.17%、0.74%、0.3%。 从解禁量来看，海思科、太力科技、威高血净解禁量居前，解禁股数分别为174.0万股、126.39万股、 125.47万股。 从解禁市值来看，海思科、威高血净、太力科技解禁市值居前，解禁市值分别为9516.06万元、5163.28 万元、4873.58万元。 每经AI快讯，Wind数据显示，周三（11月19日），共有7家公司限售股解禁，合计解禁量为559.92万 股，按最新收盘价计算，合计解禁市值为2.25亿元。 ...

Group 1 - The core viewpoint of the news is that Weigao Blood Purification experienced a slight decline in stock price and had notable financing activities on November 17, 2023 [1] - On November 17, Weigao Blood Purification's stock price fell by 0.12%, with a trading volume of 93.22 million yuan [1] - The financing data shows that on the same day, the company had a financing buy-in amount of 9.41 million yuan and a financing repayment of 12.99 million yuan, resulting in a net financing buy of -3.58 million yuan [1] Group 2 - As of November 17, 2023, the total balance of margin trading for Weigao Blood Purification was 165 million yuan, accounting for 10.40% of its circulating market value [1] - The company has not engaged in any short selling activities on November 17, with no shares sold or repaid [1] - Weigao Blood Purification, established on December 27, 2004, specializes in the research, production, and sales of medical products for blood purification, with its main revenue sources being consumables (77.55%), equipment (18.25%), and others (4.60%) [1] Group 3 - As of September 30, 2023, Weigao Blood Purification had 24,800 shareholders, a decrease of 20.95% from the previous period, while the average circulating shares per person increased by 26.51% to 1,535 shares [2] - For the period from January to September 2023, the company achieved an operating income of 2.736 billion yuan, representing a year-on-year growth of 3.45%, and a net profit attributable to the parent company of 341 million yuan, up 7.92% year-on-year [2] - Since its A-share listing, Weigao Blood Purification has distributed a total of 65.82 million yuan in dividends [2]

Core Insights - The performance of newly listed companies in the A-share market has shown a stark contrast, with some experiencing significant gains while others have plummeted to new lows shortly after their IPOs [1][5][9] Group 1: Market Performance of New Listings - Deli Jia, a leading wind power gearbox manufacturer, saw its stock price drop significantly after an initial surge, reaching a new low of 62.48 yuan after its IPO [1] - In 2025, among 92 newly listed companies, only one has increased by over 18 times, while 5 companies, including Deli Jia, have dropped to new lows shortly after listing [1] - Haibo Shichuang, a battery storage system company, has become a standout performer with a stock price increase of 1855.6% since its IPO in January [3] Group 2: Factors Influencing Stock Performance - The disparity in stock performance is attributed to industry trends and company fundamentals, with successful companies often aligned with current market hotspots, such as energy storage [7] - Companies facing challenges, such as those in the wind power sector, have seen their stock prices decline due to insufficient performance support [7] - The pricing and valuation of new stocks have raised concerns, with some companies having significantly higher price-to-earnings ratios compared to industry leaders, leading to market skepticism [7] Group 3: Investor Behavior and Market Dynamics - The new stock market environment has shifted, with 73% of new stocks in 2025 dropping below their first-day closing price, indicating a departure from the previous "guaranteed profit" mentality [9] - Retail investors have contributed significantly to trading volumes but lack pricing power, often buying at high prices after institutional investors sell [7][11] - The introduction of a five-day period without price limits for new stocks has created opportunities for extreme volatility, allowing for both rapid gains and losses [9][11]

Group 1 - The CITIC Pharmaceutical Index increased by 3.29%, outperforming the CSI 300 Index by 4.37 percentage points, ranking 3rd among 30 primary industries [1] - The top ten stocks with the highest gains this week include Jindike, Renmin Tongtai, Chengda Pharmaceutical, Hefuchina, Fuxiang Pharmaceutical, Te Yi Pharmaceutical, Yao Yigou, Bohui Innovation, Shuyupingmin, and Haichen Pharmaceutical [1] - The top ten stocks with the largest declines this week include *ST Changyao, Zhend Medical, Heyuan Biological-U, Weigao Blood Purification, Furui Shares, Ruimaite, Microelectrophysiology, Botuo Biological, Bibete-U, and Shuoshi Biological [1] Group 2 - On November 10, Guangshentang Pharmaceutical's core drug, the oral small molecule hepatitis B surface antigen inhibitor GST-HG131, had its Phase II clinical data selected for the AASLD annual meeting's latest breakthrough summary and was reported on-site [1] - GST-HG131 is the first oral drug in global hepatitis B clinical breakthrough research that significantly reduces HBsAg in hepatitis B patients, with 76.5% of patients achieving levels below 100 IU/ml within three months, attracting attention from many multinational pharmaceutical companies for potential collaboration [1] Group 3 - On November 10, Roche announced that its third-generation BTK inhibitor Fenebrutinib met primary endpoints in two Phase III studies (FENhance 2 and FENtrepid) for treating relapsing multiple sclerosis (RMS) [2] - Results showed that at week 96, the annualized relapse rate (ARR) for patients on Fenebrutinib was significantly lower compared to those on teriflunomide, and at week 120, Fenebrutinib was non-inferior to Ocrevus in delaying disability progression in primary progressive multiple sclerosis (PPMS) patients [2] - Pfizer announced the successful completion of its $9.2 billion acquisition of Metsera, a biopharmaceutical company focused on developing next-generation treatments for obesity and cardiovascular metabolic diseases [2] - This acquisition adds a series of potential candidates highly complementary to Pfizer's existing internal medicine pipeline, including MET-097i, a weekly or monthly injectable GLP-1 receptor agonist entering Phase III trials, and MET-233i, a monthly amylin analog currently in Phase I evaluation [2]

根据中国证券监督管理委员会《关于同意山东威高血液净化制品股份有限公司首次公开发行股票注册的 批复》（证监许可〔2025〕526号），并经上海证券交易所同意，山东威高血液净化制品股份有限公司 （以下简称"公司"）首次向社会公开发行人民币普通股（A股）41,139,407股，并于2025年5月19日在上 海证券交易所主板上市，发行完成后总股本为411,394,066股，其中有限售条件流通股373,281,479股，无 限售条件流通股38,112,587股。 ● 本次股票上市类型为首发股份；股票认购方式为网下，上市股数为1,254,745股。 本次股票上市流通总数为1,254,745股。 ● 本次股票上市流通日期为2025年11月19日。 一、本次限售股上市类型 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603014 证券简称：威高血净公告编号：2025-043 山东威高血液净化制品股份有限公司 首次公开发行网下配售限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次解除限售 ...

（文章来源：证券日报） 证券日报网讯 11月12日晚间，威高血净发布公告称，本次股票上市类型为首发股份；股票认购方式为 网下，上市股数为1，254，745股。本次股票上市流通总数为1，254，745股。本次股票上市流通日期为 2025年11月19日。 ...

证券代码：603014 证券简称：威高血净 公告编号：2025-043 山东威高血液净化制品股份有限公司 首次公开发行网下配售限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为 首发 股份；股票认购方式为 网下 ，上市股数为 1,254,745股。 本次股票上市流通总数为1,254,745股。 本次股票上市流通日期为2025 年 11 月 19 日。 一、本次限售股上市类型 根据中国证券监督管理委员会《关于同意山东威高血液净化制品股份有限公 司首次公开发行股票注册的批复》（证监许可〔2025〕526 号），并经上海证券交 易所同意，山东威高血液净化制品股份有限公司（以下简称"公司"）首次向社会公 开发行人民币普通股（A 股）41,139,407 股，并于 2025 年 5 月 19 日在上海证券交 易所主板上市，发行完成后总股本为 411,394,066 股，其中有限售条件流通股 373,281,479 股，无限售条件流通股 38,112,587 股。 本次解除限售并上市 ...